Mumbai: Biopharmaceutical major, Biocon on Saturday said that it has received the Drugs Controller General of Indias (DCGI) approval to market Itolizumab (ALZUMAb) Injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due...